Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)

Zhang, Lin; Mao, Wei; Liu, Dan; Hu, Bin; Lin, Xiaofang; Ran, Jie; Li, Xingxing; Hu, Jing

doi:10.3389/fphar.2023.1231320

Cited by 3 publications

(2 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AZA, an immunosuppressant agent used in managing various autoimmune conditions such as rheumatoid arthritis, lupus, Chron's disease and ulcerative colitis, and in the context of transplants, appears to be a useful drug for preventing relapse in AIP ( 33 ), according to reports from numerous cases and small case series ( 54 , 55 ). This association raises marked concerns regarding its safety in patients with AIP ( 56 ).…”

Section: Discussionmentioning

confidence: 99%

Treatment approaches in autoimmune pancreatitis (Review)

Pădureanu,

Drăgoescu,

Pădureanu

et al. 2023

Biomed Rep

View full text Add to dashboard Cite

Autoimmune pancreatitis (AIP) is a rare disease. There are two distinct types of AIP: AIP type 1 (AIP-1), a pancreatic manifestation of a multi-organ disease linked to immunoglobulin (Ig)G4, and AIP type 2 (AIP-2), a pancreas-specific disease unrelated to IgG4. The usual course of treatment for AIP is oral corticosteroid medication. Rituximab has also been recommended for recurrent AIP-1 in order to initiate remission and provide ongoing treatment. Immunomodulators such as azathioprine are used to keep certain patients in remission. Evaluation also takes into account a number of pharmacological alternatives, including biologic drugs like anti-tumor necrosis factor therapy, a safe and efficient second-line treatment for AIP-2 relapse or steroid dependence. Corticosteroids and immunosuppressants, which are poorly tolerated due to considerable side effects, are being replaced by other biologic drugs, which may offer a beneficial therapeutic alternative.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment approaches in autoimmune pancreatitis (Review)

Pădureanu,

Drăgoescu,

Pădureanu

et al. 2023

Biomed Rep

View full text Add to dashboard Cite

show abstract

“…Pancreatitis has several risk factors, including gallstones, alcohol abuse, smoking, hypertriglyceridemia, and some medications. Furthermore, patients with diabetes mellitus (DM) have a higher chance of developing pancreatitis compared with those who have no DM ( Zhang, et al, 2023 ). Also, there is evidence suggesting that DM is also a risk factor for pancreatic cancer (Shen, et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database

Alenzi,

Alsuhaibani,

Batarfi

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Pancreatitis is characterized by inflammation of the pancreas and significantly affects quality of life. Less than 5% of pancreatitis cases are drug-induced, but recent evidence suggests a substantial risk associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The aim of this study was to compare the risk of developing pancreatitis between those using GLP-1 RAs and those using sodium-glucose transport protein 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors.Methods: This study was done using the FDA Adverse Event Reporting System (FAERS) database from 2019 to 2021. This database contains information from diverse submissions from healthcare providers, patients, and manufacturers. To ensure fairness and accuracy, the risk of pancreatitis associated with other hypoglycemic agents (SGLT2 inhibitors and DPP-4 inhibitors) was also investigated. Traditional and Bayesian statistical analysis methods were used to identify disproportionate statistics and included the reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM), and information component (IC). A drug–adverse-event combination that met the criteria of all four indices was deemed a signal.Results: The analysis of 2,313 pancreatitis reports linked to hypoglycemic agents revealed a predominant association with GLP-1 RA (70.2%) compared to DPP-4 inhibitors (15%) and SGLT2 (14.7%). Most of these reports involved female patients (50.4%), and the highest incidence occurred in those over 50 years old (38.4%). Additionally, 17.7% of the reports were associated with serious events. The ROR was significant for the risk of pancreatitis when using DPP-4 (13.2, 95% confidence interval (CI) 11.84-14.70), while the ROR for GLP-1 was 9.65 (95% CI 9.17-10.16). The EBGM was highest with DPP-4 (12.25), followed by GLP-1 (8.64), while IC was highest with DPP-4 inhibitors (3.61). Liraglutide had the greatest association with pancreatitis among the GLP-1 RAs (ROR: 6.83, 95% CI 6.60-7.07).Conclusion: The findings show that pancreatitis has a strong link with DPP-4 inhibitors and GPL1 agonists, which pose a greater risk. Among the GLP-1 agonist medications, liraglutide has been found to have an association with pancreatitis.

show abstract